Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) FCF Margin (2016 - 2026)

Integra Lifesciences Holdings' FCF Margin history spans 17 years, with the latest figure at 1.24% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 602.0% to 1.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.9%, a 345.0% decrease, with the full-year FY2025 number at 1.9%, down 345.0% from a year prior.
  • FCF Margin hit 1.24% in Q4 2025 for Integra Lifesciences Holdings, down from 6.4% in the prior quarter.
  • Over the last five years, FCF Margin for IART hit a ceiling of 21.71% in Q2 2021 and a floor of 10.5% in Q1 2025.
  • Historically, FCF Margin has averaged 7.1% across 5 years, with a median of 5.59% in 2024.
  • Biggest five-year swings in FCF Margin: surged 1612bps in 2021 and later tumbled -1178bps in 2023.
  • Tracing IART's FCF Margin over 5 years: stood at 10.32% in 2021, then soared by 73bps to 17.81% in 2022, then tumbled by -52bps to 8.62% in 2023, then crashed by -45bps to 4.78% in 2024, then crashed by -126bps to 1.24% in 2025.
  • Business Quant data shows FCF Margin for IART at 1.24% in Q4 2025, 6.4% in Q3 2025, and 2.7% in Q2 2025.